CordycepsPrime™ (Fermented Cordyceps sinensis Mycelium Extract)

Cordyceps sinensis (Ophiocordyceps sinensis), fermented mycelium
Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

CordycepsPrime™ is NuLiv Science's fermented Cordyceps sinensis mycelium extract, made by liquid fermentation and standardized by the supplier to 10 percent cordycepic acid. Cordycepic acid is D-mannitol, a sugar alcohol, so that number describes neither cordycepin nor adenosine nor polysaccharide content. The material is not Cordyceps militaris and it is not wild caterpillar fungus. No clinical trial of CordycepsPrime itself has been published: searches of PubMed and Europe PMC for the trade name return zero records. Everything below therefore comes from other companies' cordyceps products. On exercise, most of it is null. In 96 healthy young adults, a C. sinensis plus Ganoderma lucidum supplement changed nothing on VO2max, peak power, mean power or fatigue index. In 17 trained cyclists, and again in 8 male cyclists, a Cs-4 plus Rhodiola rosea formula changed nothing on VO2, time to exhaustion or muscle oxygen saturation. A 12-week pilot in 20 older adults on a different Cs-4 brand raised metabolic and ventilatory thresholds within the treated group but showed no significant difference against placebo, and no change in VO2max. The one clearly positive VO2max result came from a six-mushroom blend built on Cordyceps militaris, a different species at eight times the dose, and only in the 10 people who continued to 3 weeks. Where cordyceps has produced a positive randomized result in healthy adults is on immune laboratory markers: a cultured Cordyceps sinensis mycelium extract from another company raised natural killer cell activity in 79 healthy adults over 8 weeks. The 500 mg label dose has never been tested.

Studied Dose The supplier lists 500 mg/day, but no published trial has used that dose or this material. The doses that were actually tested, roughly 1 to 4 g/day, all belong to other cordyceps products (mostly Cs-4 and Cordyceps militaris blends), not to this ingredient.
Active Compound Fermented Cordyceps sinensis mycelium, grown by liquid fermentation rather than on a grain substrate, so it carries no residual grain. NuLiv Science standardizes it to 10 percent cordycepic acid. Cordycepic acid is D-mannitol, a common sugar alcohol found across medicinal mushrooms, so the 10 percent figure is a batch-consistency marker rather than a measure of anything cordyceps-specific. NuLiv also lists beta-glucans as an active but publishes no percentage for them, and publishes no adenosine or cordycepin figure. Cordycepin is a Cordyceps militaris compound: Cordyceps sinensis mycelium makes little or none of it.

Benefits

Exercise capacity: measured in humans, mostly no effect

Exercise capacity is the only performance outcome cordyceps has been tested for in healthy people, and the results are mostly negative. The largest trial (96 physical education students, 28 to 33 days) found no effect of a Cordyceps sinensis plus Ganoderma lucidum supplement on VO2max, peak power, mean power or fatigue index. Two reports on a Cs-4 plus Rhodiola formula in cyclists (17 and 8 men) found no effect on VO2, time to exhaustion, ventilatory threshold or muscle oxygen saturation. A 12-week pilot in 20 older adults taking 999 mg per day of Cs-4 raised metabolic and ventilatory thresholds within the treated group, but the between-group comparison was not significant and VO2max did not move. The one positive VO2max result used Cordyceps militaris inside a six-mushroom blend, and only in the 10 people (6 on the blend, 4 on placebo) who continued to 3 weeks. In the first week of that same study, the placebo group's VO2max rose more than the supplement group's. None of these studies used CordycepsPrime.

Daily energy and stamina: never measured in a trial

Cordyceps is a traditional tonic in Chinese medicine and is marketed as an adaptogenic energy ingredient. No randomized placebo-controlled trial has measured subjective energy, vitality or fatigue in healthy adults taking any cordyceps product. This claim rests on tradition and on marketing, not on a measurement.

Breathing: studied only in people with diagnosed lung disease

Traditional Chinese use of cordyceps for the lung is traditional use, not evidence. The human respiratory research that exists was done entirely in patients with diagnosed disease: a 48-week placebo-controlled trial of a Cordyceps sinensis capsule at 6 g per day in 238 people with chronic bronchitis, a 3-month controlled study in 120 people with moderate-to-severe asthma who were already on inhaled corticosteroids, and a meta-analysis of 15 studies in 1,238 people with stable COPD whose authors noted that no included study was placebo-controlled or of high methodological quality. None of that is a result in a healthy person, none of it used CordycepsPrime, and none of it is a reason for a healthy reader to take this product for breathing.

Recovery: one 14-person study of muscle repair markers

Some athletes use cordyceps during heavy training blocks. There is one human study: a randomized, double-blind, placebo-controlled crossover in 14 young adults given 1 g of Cordyceps sinensis or 1 g of cornstarch before high-intensity interval cycling. Muscle biopsies showed less necrotic cell infiltration 3 hours after exercise on cordyceps, earlier recruitment of CD34+ progenitor cells, and a four-fold expansion in Pax7+ cell count. Those are tissue repair markers read off a biopsy, not soreness, strength or training gains, and no trial has measured whether cordyceps improves recovery across a training block. None of it used CordycepsPrime.

Mechanism of action

1

Adenosine and mannitol (cordycepin is a C. militaris compound)

Cordycepin (3'-deoxyadenosine) is abundant in Cordyceps militaris and scarce in Cordyceps sinensis, so it is not the operative compound in a fermented C. sinensis mycelial extract like this one. What C. sinensis material carries is adenosine and D-mannitol, the compound the label calls cordycepic acid. Adenosine acts on adenosine receptors in laboratory work relevant to vasodilation and cellular energy metabolism. None of this has been shown to produce a measurable effect in people taking this ingredient.

2

Polysaccharide immunomodulation

Cordyceps polysaccharides are reported to engage innate immune receptors (similar to other fungal beta-glucans) and modulate cytokine production in animal and cell models, providing a mechanistic basis for traditional immune-supportive claims.

3

Mitochondrial bioenergetic support

Preclinical work suggests cordyceps constituents may support mitochondrial respiration and reduce exercise-induced oxidative stress, but the controlled human exercise trials that have been run were largely null, so this mechanism has not translated.

Clinical trials

1
Six-mushroom blend (PeakO2, contains Cordyceps militaris): RCT in a different species and a competitor's brand
PubMed

Randomized, double-blind, placebo-controlled trial of PeakO2 (Compound Solutions), a 4 g/day blend of six mushroom mycelia cultured on organic oats: Cordyceps militaris, Ganoderma lucidum, Pleurotus eryngii, Lentinula edodes, Hericium erinaceus and Trametes versicolor. The Cordyceps militaris content of the blend was not disclosed. 28 participants completed the 1-week phase (13 blend, 15 placebo); 10 of them volunteered to continue to 3 weeks (6 blend, 4 placebo). Funded by Disruptive Nutrition, Burlington NC. Journal of Dietary Supplements 2017;14(1):42-53.

28 recreationally active adults at the 1-week timepoint (13 blend, 15 placebo); only 10 continued to the 3-week timepoint, split 6 on the blend and 4 on placebo, which is where the positive result appeared.

After 1 week there was no significant time by treatment interaction for VO2max (p = 0.364), ventilatory threshold (p = 0.514), time to exhaustion (p = 0.540), peak power (p = 0.134), average power (p = 0.398) or percent drop (p = 0.823), and the placebo group's VO2max actually rose more than the blend group's over that week. After 3 weeks, in the 10 people who continued (6 blend, 4 placebo), there was a significant time by treatment interaction for VO2max, which rose 4.8 mL/kg/min on the blend versus 0.9 on placebo (p = 0.042). Time to exhaustion showed no significant interaction at either 1 week (p = 0.540) or 3 weeks (p = 0.261); the reported gains came from a within-group 95 percent confidence interval analysis. This study used a different species (Cordyceps militaris), a different company's blend of six mushrooms rather than cordyceps alone, and 4 g/day against CordycepsPrime's 500 mg label. It does not transfer to this product.

2
NOT A STUDY: no clinical trial of CordycepsPrime exists

This entry describes no study. A PubMed search and a Europe PMC search for the trade name CordycepsPrime each returned zero records, and NuLiv Science publishes no citation for the ingredient on its product page. The supplier's trade listings describe CordycepsPrime as clinically researched; no such research is publicly available.

None. No participants have ever been enrolled in a trial of this ingredient.

There are no findings. Anyone buying CordycepsPrime is buying a fermented Cordyceps sinensis mycelium extract that has never been tested in people. The cordyceps exercise trials that do exist in healthy adults have mostly reported no effect, and the positive human results for this species are on immune laboratory markers rather than on performance.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated at typical dietary supplement doses. Cordyceps is a fungus: avoid it if you react to moulds or edible mushrooms.
Mild GI symptoms (nausea, dry mouth) possible in sensitive individuals.
Theoretical immune-system stimulation — caution in autoimmune conditions.
No safety data of any kind exist for CordycepsPrime specifically. The longest placebo-controlled exposure for any Cordyceps sinensis preparation is 48 weeks at 6 g/day in 238 chronic bronchitis patients, where adverse events were no more frequent than on placebo (29.6 percent versus 30.4 percent).
Discontinue if an allergic reaction or unexpected respiratory symptoms develop. Separately, heavy metal contamination, chiefly arsenic, is a documented problem in wild-harvested Ophiocordyceps sinensis, to the point that arsenic content is used analytically to tell wild from cultivated material. CordycepsPrime is a fermented mycelium rather than wild caterpillar fungus, so that particular risk does not apply here, but it is worth checking heavy metal testing on any cordyceps sold as wild or as caterpillar fungus.

Important Drug interactions

Immunosuppressants (cyclosporine, tacrolimus) — theoretical antagonism via immunomodulation; discuss with clinician.
Anticoagulants and antiplatelet agents: cordyceps fungi show antiplatelet and antithrombotic activity in animal and cell studies. No bleeding events were reported in the human cordyceps trials described on this page, including a 48-week trial at 6 g per day. Treat it as a theoretical risk and tell your prescriber if you take a blood thinner.
Antidiabetic medications — possible mild glucose-lowering effect; monitor blood sugar.
Stimulant medications — theoretical additive energy effect; monitor cardiovascular tolerance.

Frequently asked questions about CordycepsPrime™ (Fermented Cordyceps sinensis Mycelium Extract)

What is CordycepsPrime?

CordycepsPrime™ is NuLiv Science's fermented Cordyceps sinensis mycelium extract, made by liquid fermentation and standardized by the supplier to 10 percent cordycepic acid. Cordycepic acid is D-mannitol, a sugar alcohol, so that number describes neither cordycepin nor adenosine nor polysaccharide content.

What is CordycepsPrime used for?

CordycepsPrime is researched primarily for Immune Support and Muscle & Recovery. Exercise capacity is the only performance outcome cordyceps has been tested for in healthy people, and the results are mostly negative.

What is the recommended dosage of CordycepsPrime?

The clinically studied dose is The supplier lists 500 mg/day, but no published trial has used that dose or this material. The doses that were actually tested, roughly 1 to 4 g/day, all belong to other cordyceps products (mostly Cs-4 and Cordyceps militaris blends), not to this ingredient. Always follow the product label and check with a healthcare provider for personal advice.

Is CordycepsPrime safe, and does it have side effects?

For most healthy adults, CordycepsPrime is well tolerated at studied doses. Reported effects can include: Generally well tolerated at typical dietary supplement doses. Cordyceps is a fungus: avoid it if you react to moulds or edible mushrooms. Mild GI symptoms (nausea, dry mouth) possible in sensitive individuals. It may also interact with some medications. CordycepsPrime is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does CordycepsPrime interact with any medications?

Possible interactions include: Immunosuppressants (cyclosporine, tacrolimus) — theoretical antagonism via immunomodulation; discuss with clinician. Anticoagulants and antiplatelet agents: cordyceps fungi show antiplatelet and antithrombotic activity in animal and cell studies. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for CordycepsPrime?

NutraSmarts rates the evidence for CordycepsPrime as Limited (2 out of 5). It is backed by 2 clinical trials and 9 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(9 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Hirsch KR, Smith-Ryan AE, Roelofs EJ, Trexler ET, Mock MG. Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation. J Diet Suppl. 2017;14(1):42-53. doi: 10.1080/19390211.2016.1203386.PubMedUsed to support: Randomised, double-blind, placebo-controlled trial in 28 recreationally active adults of PeakO2 (Compound Solutions), a 4 g/day blend of six mushroom mycelia grown on organic oats, of which Cordyceps militaris was one and its content was not disclosed. After 1 week there was no significant time by treatment interaction for VO2max, ventilatory threshold, time to exhaustion, peak power, average power or percent drop, and the placebo group's VO2max rose more than the blend group's over that week. Ten participants continued to 3 weeks (6 on the blend, 4 on placebo), and in that subgroup VO2max rose 4.8 mL/kg/min versus 0.9 on placebo (p = 0.042). Time to exhaustion showed no significant interaction at either timepoint. The trial was funded by Disruptive Nutrition. It tested Cordyceps militaris, a different species from the Cordyceps sinensis mycelium in this product, inside a multi-mushroom blend at eight times the label dose.
  2. Colson SN, Wyatt FB, Johnston DL, Autrey LD, FitzGerald YL, Earnest CP. Cordyceps sinensis- and Rhodiola rosea-based supplementation in male cyclists and its effect on muscle tissue oxygen saturation. J Strength Cond Res. 2005;19(2):358-63. doi: 10.1519/R-15844.1.PubMedUsed to support: Double-blind, randomised, placebo-controlled study in 8 male cyclists of a formula combining Cordyceps sinensis (Cs-4) and Rhodiola rosea, tested during two maximal cycle ergometer tests to volitional fatigue. There were no significant differences in muscle tissue oxygen saturation slope or threshold, VO2max, ventilatory threshold or time to exhaustion, either between the treatment and control groups or within them. The authors concluded the combination did not enhance muscle tissue oxygen saturation. Because Rhodiola rosea was given alongside the cordyceps, nothing in this result can be attributed to cordyceps on its own.
  3. Earnest CP, Morss GM, Wyatt F, Jordan AN, Colson S, Church TS, Fitzgerald Y, Autrey L, Jurca R, Lucia A. Effects of a commercial herbal-based formula on exercise performance in cyclists. Med Sci Sports Exerc. 2004;36(3):504-9. doi: 10.1249/01.mss.0000125157.49280.af.PubMedUsed to support: Randomised, double-blind, placebo-controlled trial in 17 competitive amateur cyclists of a commercial formula whose main ingredients were 1,000 mg Cordyceps sinensis (Cs-4) and 300 mg Rhodiola rosea per three-capsule daily dose, after a 4-day loading phase and 11 days of maintenance. There was no significant treatment effect on peak VO2, time to exhaustion, peak power output, peak heart rate, ventilatory threshold, or power at 2 and 4 mmol/L blood lactate. The authors concluded a 2-week schedule was insufficient to change cycling performance. Because Rhodiola and several other ingredients were included, nothing in this study can be assigned to cordyceps alone.
  4. Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB. Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med. 2010;16(5):585-90. doi: 10.1089/acm.2009.0226.PubMedUsed to support: The closest preparation match to CordycepsPrime, though a different brand: 20 healthy adults aged 50 to 75 took Cs-4 fermented Cordyceps sinensis mycelium 333 mg three times daily (999 mg/day) or placebo for 12 weeks, with 15 completing. Metabolic threshold rose 10.5 percent and ventilatory threshold 8.5 percent within the Cs-4 group, while the placebo group did not change significantly, but multivariable analysis found no statistically significant difference between the groups and VO2max did not change in either. The authors describe it as a pilot study and note the sample was too small for convincing evidence. The Cs-4 was supplied by Pharmanex.
  5. Wang N, Li J, Huang X, Chen W, Chen Y. Herbal Medicine Cordyceps sinensis Improves Health-Related Quality of Life in Moderate-to-Severe Asthma. Evid Based Complement Alternat Med. 2016;2016:6134593. doi: 10.1155/2016/6134593.PubMedUsed to support: 120 patients with moderate-to-severe persistent asthma were randomised to receive a Cordyceps sinensis capsule for 3 months in addition to inhaled corticosteroids and as-needed beta-agonists, or to the same background therapy without it. Asthma quality-of-life scores and lung function improved in the cordyceps group relative to control, with lower serum IgE, ICAM-1, IL-4 and MMP-9. The control group received no placebo, so the comparison is open-label, and the participants were asthma patients on prescription inhalers rather than healthy adults.
  6. Tsuk S, Lev YH, Rotstein A, Zeev A, Carasso R, Steiner G. Effects of a Commercial Supplement of Ophiocordyceps sinensis and Ganoderma lucidum on Physiological Responses to Maximal Exercise in Healthy Young Participants. Int J Med Mushrooms. 2018;20(4):359-367. doi: 10.1615/IntJMedMushrooms.2018025989.PubMedUsed to support: The largest exercise trial of Cordyceps sinensis in healthy adults: 96 physical education students randomised to low-dose supplement, high-dose supplement or placebo for 28 to 33 days. The supplement, a commercial combination of Ophiocordyceps sinensis and Ganoderma lucidum, had no effect on VO2max or on any physiological response during a graded maximal treadmill test, and no effect on peak power, mean power or fatigue index on the Wingate anaerobic test.
  7. Guo LX, Zhang GW, Li QQ, Xu XM, Wang JH. Novel Arsenic Markers for Discriminating Wild and Cultivated Cordyceps. Molecules. 2018;23(11):2804. doi: 10.3390/molecules23112804.PubMedUsed to support: Total arsenic and arsenic species were measured by ICP-MS and HPLC-ICP-MS in cultivated Ophiocordyceps sinensis, Cordyceps militaris and other edible fungi. Arsenic speciation differed by species, and the authors report that arsenic testing has become a necessary check on whether inorganic arsenic in Ophiocordyceps sinensis exceeds its limit, with total arsenic and the proportion of unknown organic arsenic proposed as markers for identifying wild material. Relevant to buyers of wild-harvested caterpillar fungus rather than to fermented mycelial products.
  8. Yu X, Mao Y, Shergis JL, Coyle ME, Wu L, Chen Y, Zhang AL, Lin L, Xue CC, Xu Y. Effectiveness and Safety of Oral Cordyceps sinensis on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2019;2019:4903671. doi: 10.1155/2019/4903671.PubMedUsed to support: Systematic review and meta-analysis of 15 interventional studies totalling 1,238 participants with stable COPD of GOLD stages 2 to 3, testing oral Cordyceps sinensis alone or combined with other herbs. Pooled results showed potential benefit for lung function, exercise endurance, quality of life and symptoms, with no serious adverse events reported. The authors state that no included study was placebo-controlled or of high methodological quality, which limits what can be concluded. This is a review of studies in diagnosed COPD patients, not a trial and not a healthy-adult result.
  9. Shu X, Xu D, Qu Y, Shang X, Qiao K, Feng C, Cui H, Zhao X, Li Y, Peng Y, Li D, Zhang H. Efficacy and safety of Cordyceps sinensis (Hirsutella sinensis, Cs-C-Q80) in chronic bronchitis. Front Pharmacol. 2024;15:1428216. doi: 10.3389/fphar.2024.1428216.PubMedUsed to support: Randomised, double-blind, placebo-controlled trial across eight Chinese hospitals in patients with chronic bronchitis, a diagnosed lung disease. 240 were randomised 2:1 and 238 analysed (159 on the Cordyceps sinensis capsule, 79 on placebo), taking 2.0 g three times daily for 48 weeks. Acute exacerbations during treatment averaged 0.43 per patient on the capsule versus 1.56 on placebo (p < 0.001), and expectoration and wheezing severity improved. Adverse events were similar between groups (29.6 percent versus 30.4 percent). This was a patient population on a 6 g per day dose of a different preparation, not a healthy-adult supplement result.